News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

SUBSCRIBE

SUBSCRIBE

News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

Search Query

Search Results

Looking for jobs? Search jobs

8,476 Results

Type

Article (346)
Press Release (8130)

Section

Business (2609)
Career Advice (1)
Deals (624)
Drug Development (908)
Employer Resources (1)
FDA (213)
Job Trends (74)
News (4347)
Policy (289)

Tag

Date

Last 7 days (9)
Last 30 days (23)
Last 365 days (370)
2025 (44)
2024 (379)
2023 (414)
2022 (623)
2021 (656)
2020 (599)
2019 (388)
2018 (297)
2017 (478)
2016 (473)
2015 (597)
2014 (408)
2013 (410)
2012 (406)
2011 (333)
2010 (264)

Location

Africa (8)
Arizona (2)
Asia (630)
Australia (115)
California (22)
Canada (39)
China (5)
Europe (2245)
Florida (9)
Georgia (2)
Indiana (2)
Maryland (6)
Massachusetts (42)
New Jersey (2)
New York (9)
North Carolina (29)
Northern California (11)
Pennsylvania (9)
South America (13)
Southern California (9)
Tennessee (13)
Texas (6)
Washington State (6)

Filters

Type

Article (346)
Press Release (8130)

Section

Business (2609)
Career Advice (1)
Deals (624)
Drug Development (908)
Employer Resources (1)
FDA (213)
Job Trends (74)
News (4347)
Policy (289)

Tag

Date

Last 7 days (9)
Last 30 days (23)
Last 365 days (370)
2025 (44)
2024 (379)
2023 (414)
2022 (623)
2021 (656)
2020 (599)
2019 (388)
2018 (297)
2017 (478)
2016 (473)
2015 (597)
2014 (408)
2013 (410)
2012 (406)
2011 (333)
2010 (264)

Location

Africa (8)
Arizona (2)
Asia (630)
Australia (115)
California (22)
Canada (39)
China (5)
Europe (2245)
Florida (9)
Georgia (2)
Indiana (2)
Maryland (6)
Massachusetts (42)
New Jersey (2)
New York (9)
North Carolina (29)
Northern California (11)
Pennsylvania (9)
South America (13)
Southern California (9)
Tennessee (13)
Texas (6)
Washington State (6)

8,476 Results for "synaffix bv".

Sort By

SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology

SOTIO, a clinical-stage immuno-oncology company owned by PPF Group, announced a license and option agreement with Synaffix B.V., a Lonza company, to develop next-generation antibody-drug conjugates for the treatment of solid tumors.

October 16, 2023
·
5 min read
Drug Development

Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study

Innovent Biologics, Inc. announces the licensing deal expansion with Synaffix B.V., a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates with best-in-class therapeutic index.

December 6, 2023
·
6 min read
Collaboration

Boehringer Ingelheim Expands Cancer Pipeline With Back-to-Back Antibody Deals

On Thursday, Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth license option under a 2013 collaboration with Oxford BioTherapeutics.

January 10, 2025
·
2 min read
·
Tristan Manalac
Press Releases

Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent

February 21, 2025
·
11 min read
Press Releases

Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

December 30, 2024
·
5 min read
Press Releases

MilliporeSigma Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio

January 7, 2025
·
3 min read
Press Releases

MilliporeSigma to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio

December 17, 2024
·
5 min read
Pharm Country

Amring Pharmaceuticals Inc. Announces Name Change to Nordic Pharma, Inc. Under New Nordic Group, B.V. Ownership

Amring Pharmaceuticals Inc. (“Amring”) announces its name change to Nordic Pharma, Inc. on March 4, 2024, following the change in ownership of the company from SEVER Life Sciences, B.V. to Nordic Group, B.V., a subsidiary of SEVER Life Sciences B.V., which occurred on June 1, 2023.

March 4, 2024
·
3 min read
Business

Genmab and Synaffix Enter into License Agreement for ADC Technology

Genmab A/S (Nasdaq: GMAB) and Synaffix B.V., announced today that Genmab and Synaffix have signed a license agreement providing Genmab broad access to Synaffix’s ADC technologies.

January 4, 2022
·
6 min read
Pharm Country

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces the Launch of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye.

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.

May 29, 2024
·
3 min read

1 of 848

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

Explore
About
More

© 1985 - 2025 BioSpace.com. All rights reserved.

twitter
instagram
facebook
linkedin